Thymosin Alpha-1: what the published research shows
A research summary of published preclinical and clinical literature on Thymosin Alpha-1 (Tα1), covering its reported receptor engagement, immunomodulatory mechanisms, and the trial settings in which it has been studied.
Thymosin Alpha-1 (Tα1), also written thymalfasin and thymosin α-1, is a thymus-derived peptide hormone of the immunomodulatory peptide class. It is an acetylated 28-amino-acid peptide, and the published literature describes it as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor expressed on neurons [1]. The same literature describes Tα1 as an endogenous circulating peptide whose levels are reported to fall after chemotherapy [9].
The mechanistic work centres on two receptor and signalling axes: HCRTR1 engagement on neurons with downstream suppression of Receptor-Interacting Protein Kinase 3 (RIPK3), and, in dendritic cells, chaperoning of a microRNA ligand of TLR7 [1][9].
Research Studies
Thymosin Alpha-1 and HCRTR1-mediated suppression of neuronal necroptosis
In the neuroprotection study, Tα1 was reported to function as a non-canonical ligand for HCRTR1 on neurons. Engagement of the receptor was reported to shield neurons from cell death by suppressing the activity of RIPK3, described in the paper as a central executioner of necroptosis. The authors framed this as a direct neuroprotective axis linking the thymus to the central nervous system, and stated that the physiological relevance of the pathway was highlighted in their model [1].
This is a mechanistic finding. It identifies a receptor interaction and an intracellular signalling consequence; it does not establish a clinical outcome in any human population.
Thymosin Alpha-1 and dendritic cell TLR7 signalling after chemotherapy
In the chemotherapy-immunity work, chemotherapy was reported to induce cancer cell apoptosis and release of apoptotic bodies that are poorly immunogenic or immunosuppressive, a barrier to coadministered or second-line immunotherapies. The study reported reduced circulating levels of Tα1 and described Tα1 as chaperoning a microRNA ligand of TLR7 in dendritic cells, restoring chemotherapy-induced antitumor immunity [9].
This finding is reported at the level of circulating peptide levels and dendritic cell signalling. It is a mechanistic and preclinical observation.
Thymosin Alpha-1 and immune reconstitution in aging
Aging is characterised by immune decline attributed mainly to thymic involution, the age-related shrinkage of the thymus gland, with reduced T-cell production, chronic inflammation and increased susceptibility to age-related diseases. Tα1, described as a peptide hormone produced by the thymus, is reported to exhibit immunomodulatory, anti-inflammatory and antioxidant properties. The review reports that it helps restore immune function by stimulating T-cell differentiation, enhancing thymic output, and modulating dendritic cell and macrophage activity [3].
Preclinical and clinical studies cited in that review report that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence [3]. The population in which the vaccine-response effect was observed is elderly recipients.
Thymosin Alpha-1 combined with immune checkpoint inhibitors: reported adverse events
A case report described a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events (irAEs) after treatment with sintilimab, a PD-1 inhibitor, in combination with Tα1. The presentation included high fever, rash, interstitial pulmonary edema and multiple organ failure. The authors analysed the treatment course and discussed risks and management strategies for combining immune checkpoint inhibitors with immunomodulators, highlighting the need for clinical vigilance against possible immune overactivation triggered by combination therapy [2].
This is a single-patient report. It documents an observed adverse event in one individual and the authors' interpretation of it; it does not establish incidence or causality across a population.
Thymosin Alpha-1 as an intervention for immune-related adverse events
A registered trial is exploring whether Tα1 could be used as a therapeutic option for the treatment of immune-related adverse events secondary to immune checkpoint inhibitors. The rationale given is that Tα1 has shown clinical benefits in patients whose immune functions are severely compromised or ineffective [4].
This is a trial record. It states an intended research question and a rationale; it does not report results.
Thymosin Alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma
A retrospective study set out to validate the efficacy and safety of Tα1 combined with lenvatinib plus sintilimab in the treatment of unresectable hepatocellular carcinoma. Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People's Hospital of Guangxi Zhuang Autonomous Region from January 20 were included in the analysis [10].
The design is retrospective, and the population is patients with unresectable hepatocellular carcinoma. Retrospective designs describe associations within the reviewed records rather than assigning cause.
Thymosin Alpha-1 (thymalfasin) with adebrelimab and chemotherapy in resectable esophageal squamous cell carcinoma
A prospective, single-arm, multicentre study conducted in China is enrolling patients with pathologically or cytologically confirmed resectable esophageal squamous cell carcinoma. The objective is to explore the efficacy and safety of adebrelimab combined with thymalfasin and chemotherapy as neoadjuvant therapy. The study comprises a screening period of no more than 21 days from informed consent to first study drug administration, a treatment period including neoadjuvant therapy and surgery, and a follow-up period comprising safety follow-up and survival follow-up [6].
This is a trial record describing an ongoing single-arm design. Single-arm designs do not include a randomised comparator.
Thymosin Alpha-1 in recurrent implantation failure
A clinical trial is evaluating the safety and efficacy of Tα1 as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles [7].
The population is women with unexplained RIF undergoing assisted reproduction. The record describes the intended evaluation; it does not report outcomes.
Thymosin Alpha-1 in peptide therapy reviews of endocrine and immune modulation
A review of peptide therapies in thyroid health notes that thyroid disorders, particularly autoimmune conditions such as Hashimoto's thyroiditis, are frequently associated with persistent systemic symptoms despite biochemical normalisation with standard hormone replacement, prompting investigation into adjunctive strategies targeting immune, metabolic and neuroendocrine pathways [11].
This is a review-level discussion of adjunctive strategies in a thyroid-disease population. It is context for where Tα1 appears in the literature rather than a report of a Tα1-specific outcome.
Thymosin Alpha-1 in the context of immunoinflammatory subtyping in acute aortic dissection
A prospective multicentre randomised controlled trial in acute aortic dissection is integrating multi-dimensional data to construct an AI immunoinflammatory subtyping system, with 300 patients randomly divided into two groups: an experimental group receiving subtyping-based precision therapy and a control group using empirical strategies. The rationale notes that immunoinflammatory response drives lesion progression and that current perioperative anti-inflammatory therapies are mostly empirical and poorly targeted [5].
This record describes a subtyping-directed treatment framework in an acute aortic dissection population. It is included here as the clinical context in which immunomodulatory agents are being positioned, not as a Tα1-specific finding.
Thymosin Alpha-1 in the PraG strategy for soft tissue sarcoma
A prospective, multicentre, open-label, single-arm phase II study is evaluating spatially fractionated radiotherapy combined with the PraG strategy in soft tissue sarcoma. The regimen consists of spatially fractionated radiotherapy, Toripalimab, recombinant human granulocyte-macrophage colony-stimulating factor and thymosin, with the primary objective of evaluating efficacy and safety and the secondary questions addressing clinical prognosis and the medical adverse events participants encounter [8].
The population is patients with soft tissue sarcoma. The record describes a combination regimen in which thymosin is one component among several; it does not isolate a Tα1-specific effect.
Comparison of study designs and populations
| Study | Design | Population | Reported status |
|---|---|---|---|
| HCRTR1 neuroprotection [1] | Mechanistic | Neuronal model | Finding reported |
| Dendritic cell TLR7 chaperoning [9] | Mechanistic / preclinical | Chemotherapy model | Finding reported |
| Aging and immunosenescence [3] | Review of preclinical and clinical studies | Elderly recipients | Vaccine-response effect reported |
| Sintilimab plus Tα1 [2] | Case report | One nasopharyngeal carcinoma patient | Multisystem irAEs reported |
| irAE secondary to ICIs [4] | Registered trial | Patients with irAEs | No results reported |
| Lenvatinib plus sintilimab [10] | Retrospective | Unresectable hepatocellular carcinoma | Retrospective analysis |
| Adebrelimab plus thymalfasin [6] | Prospective, single-arm, multicentre | Resectable esophageal squamous cell carcinoma | Ongoing |
| Recurrent implantation failure [7] | Clinical trial | Women with unexplained RIF undergoing IVF/ICSI | Ongoing |
| Acute aortic dissection subtyping [5] | Prospective multicentre RCT | 300 patients with acute aortic dissection | Ongoing |
| Soft tissue sarcoma PraG [8] | Prospective, open-label, single-arm phase II | Soft tissue sarcoma | Ongoing |
What the evidence does and does not establish
The receptor-level work is mechanistic and identifies HCRTR1 engagement and RIPK3 suppression in neurons [1], and microRNA ligand chaperoning at TLR7 in dendritic cells [9]. These are findings about signalling, not about clinical endpoints in a patient population.
The immunosenescence literature reports improved vaccine response in elderly recipients and mitigation of immunosenescence, drawing on preclinical and clinical studies [3]. The population is specified: elderly recipients.
Where Tα1 appears alongside immune checkpoint inhibitors, the literature includes both a reported multisystem adverse event in a single patient [2] and an ongoing trial testing Tα1 as an intervention for irAEs [4]. Those two records point in different directions and neither resolves the other.
Several records describe intended or ongoing work rather than completed outcomes: the esophageal squamous cell carcinoma study [6], the recurrent implantation failure trial [7], the acute aortic dissection subtyping RCT [5], and the soft tissue sarcoma phase II study [8]. A trial record is a statement of design and rationale.
Sources
- [1] Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis — https://pubmed.ncbi.nlm.nih.gov/42693587/
- [2] A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12883329
- [3] Aging and Thymosin Alpha-1 — https://europepmc.org/article/PMC/PMC12692621
- [4] Thymosin Alpha-1 for irAE Secondary to ICIs — https://clinicaltrials.gov/study/NCT06178146
- [5] AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection — https://clinicaltrials.gov/study/NCT07382375
- [6] Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer — https://clinicaltrials.gov/study/NCT07780721
- [7] Thymosin-α1 for Recurrent Implantation Failure — https://clinicaltrials.gov/study/NCT07675980
- [8] A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma — https://clinicaltrials.gov/study/NCT07342322
- [9] Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells — https://pubmed.ncbi.nlm.nih.gov/42295795/
- [10] The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study — https://europepmc.org/article/PMC/PMC12015295
- [11] Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation — https://pubmed.ncbi.nlm.nih.gov/42222211/
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.